Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$16.20 USD
+0.41 (2.60%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
URGN 16.20 +0.41(2.60%)
Will URGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for URGN
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
Other News for URGN
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), AnaptysBio (ANAB) and Sarepta Therapeutics (SRPT)
Maintaining Neutral: Paul Choi’s Hold Rating on UroGen Pharma Amidst Steady Projections and Upcoming FDA Review
UroGen Pharma stock slumps after pricing stock and warrants offering
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
UroGen Pharma 5M share Spot Secondary priced at $17.50